Reviews Denileukin Diftitox


No reviews yet.

Ontak Drug Description
ONTAK®
(denileukin diftitox)
Solution for Intravenous use

WARNING
SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY.
The following adverse reactions have been reported:
Serious and fatal infusion reactions. Administer Ontak in a facility equipped
and staffed for cardiopulmonary resuscitation. Immediately stop and permanently
discontinue Ontak for serious infusion reactions [see WARNINGS AND PRECAUTIONS].

Capillary leak syndrome resulting in death. Monitor weight, edema, blood
pressure and serum albumin levels prior to and during Ontak treatment [see
WARNINGS AND PRECAUTIONS ].
Loss of visual acuity and color vision [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of denileukin diftitox (Ontak)?

You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Ontak »




Ontak (denileukin diftitox), is a recombinant DNA-derived cytotoxic protein
composed of the amino acid sequences for diphtheria toxin fragments A and B
(Met1-Thr387)-His and the sequences for human interleukin-2 (IL-2;
Ala1-Thr133). It is produced in an E. coli expression
system and has a molecular weight of 58 kD. Neomycin is used in the fermentation
process but is undetectable in the final product. Ontak is supplied in single
use vials as a sterile, frozen solution intended for intravenous (IV) administration.
Each 2 mL vial of Ontak contains 300 mcg of recombinant denileukin diftitox
in a sterile solution of citric acid (20 mM), EDTA (0.05 mM) and polysorbate
20 ( < 1%) in Water for Injection, USP. The solution has a pH range of 6.9
to 7.2.Last reviewed on RxList: 12/4/2008




Ontak Drug Description
ONTAK®
(denileukin diftitox)
Solution for Intravenous use

WARNING
SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY.
The following adverse reactions have been reported:
Serious and fatal infusion reactions. Administer Ontak in a facility equipped
and staffed for cardiopulmonary resuscitation. Immediately stop and permanently
discontinue Ontak for serious infusion reactions [see WARNINGS AND PRECAUTIONS].

Capillary leak syndrome resulting in death. Monitor weight, edema, blood
pressure and serum albumin levels prior to and during Ontak treatment [see
WARNINGS AND PRECAUTIONS ].
Loss of visual acuity and color vision [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of denileukin diftitox (Ontak)?

You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Ontak »




Ontak (denileukin diftitox), is a recombinant DNA-derived cytotoxic protein
composed of the amino acid sequences for diphtheria toxin fragments A and B
(Met1-Thr387)-His and the sequences for human interleukin-2 (IL-2;
Ala1-Thr133). It is produced in an E. coli expression
system and has a molecular weight of 58 kD. Neomycin is used in the fermentation
process but is undetectable in the final product. Ontak is supplied in single
use vials as a sterile, frozen solution intended for intravenous (IV) administration.
Each 2 mL vial of Ontak contains 300 mcg of recombinant denileukin diftitox
in a sterile solution of citric acid (20 mM), EDTA (0.05 mM) and polysorbate
20 ( < 1%) in Water for Injection, USP. The solution has a pH range of 6.9
to 7.2.Last reviewed on RxList: 12/4/2008




Ontak Drug Description
ONTAK®
(denileukin diftitox)
Solution for Intravenous use

WARNING
SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY.
The following adverse reactions have been reported:
Serious and fatal infusion reactions. Administer Ontak in a facility equipped
and staffed for cardiopulmonary resuscitation. Immediately stop and permanently
discontinue Ontak for serious infusion reactions [see WARNINGS AND PRECAUTIONS].

Capillary leak syndrome resulting in death. Monitor weight, edema, blood
pressure and serum albumin levels prior to and during Ontak treatment [see
WARNINGS AND PRECAUTIONS ].
Loss of visual acuity and color vision [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of denileukin diftitox (Ontak)?

You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Ontak »




Ontak (denileukin diftitox), is a recombinant DNA-derived cytotoxic protein
composed of the amino acid sequences for diphtheria toxin fragments A and B
(Met1-Thr387)-His and the sequences for human interleukin-2 (IL-2;
Ala1-Thr133). It is produced in an E. coli expression
system and has a molecular weight of 58 kD. Neomycin is used in the fermentation
process but is undetectable in the final product. Ontak is supplied in single
use vials as a sterile, frozen solution intended for intravenous (IV) administration.
Each 2 mL vial of Ontak contains 300 mcg of recombinant denileukin diftitox
in a sterile solution of citric acid (20 mM), EDTA (0.05 mM) and polysorbate
20 ( < 1%) in Water for Injection, USP. The solution has a pH range of 6.9
to 7.2.Last reviewed on RxList: 12/4/2008




Ontak Drug Description
ONTAK®
(denileukin diftitox)
Solution for Intravenous use

WARNING
SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY.
The following adverse reactions have been reported:
Serious and fatal infusion reactions. Administer Ontak in a facility equipped
and staffed for cardiopulmonary resuscitation. Immediately stop and permanently
discontinue Ontak for serious infusion reactions [see WARNINGS AND PRECAUTIONS].

Capillary leak syndrome resulting in death. Monitor weight, edema, blood
pressure and serum albumin levels prior to and during Ontak treatment [see
WARNINGS AND PRECAUTIONS ].
Loss of visual acuity and color vision [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of denileukin diftitox (Ontak)?

You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Ontak »




Ontak (denileukin diftitox), is a recombinant DNA-derived cytotoxic protein
composed of the amino acid sequences for diphtheria toxin fragments A and B
(Met1-Thr387)-His and the sequences for human interleukin-2 (IL-2;
Ala1-Thr133). It is produced in an E. coli expression
system and has a molecular weight of 58 kD. Neomycin is used in the fermentation
process but is undetectable in the final product. Ontak is supplied in single
use vials as a sterile, frozen solution intended for intravenous (IV) administration.
Each 2 mL vial of Ontak contains 300 mcg of recombinant denileukin diftitox
in a sterile solution of citric acid (20 mM), EDTA (0.05 mM) and polysorbate
20 ( < 1%) in Water for Injection, USP. The solution has a pH range of 6.9
to 7.2.Last reviewed on RxList: 12/4/2008




Ontak Drug Description
ONTAK®
(denileukin diftitox)
Solution for Intravenous use

WARNING
SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY.
The following adverse reactions have been reported:
Serious and fatal infusion reactions. Administer Ontak in a facility equipped
and staffed for cardiopulmonary resuscitation. Immediately stop and permanently
discontinue Ontak for serious infusion reactions [see WARNINGS AND PRECAUTIONS].

Capillary leak syndrome resulting in death. Monitor weight, edema, blood
pressure and serum albumin levels prior to and during Ontak treatment [see
WARNINGS AND PRECAUTIONS ].
Loss of visual acuity and color vision [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of denileukin diftitox (Ontak)?

You may have a reaction from a denileukin diftitox injection within hours or days after receiving the injection. Call your doctor promptly if you have one or more of these symptoms: fever, chills, weakness, muscle or joint pain, nausea, vomiting, or stomach upset.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Ontak »




Ontak (denileukin diftitox), is a recombinant DNA-derived cytotoxic protein
composed of the amino acid sequences for diphtheria toxin fragments A and B
(Met1-Thr387)-His and the sequences for human interleukin-2 (IL-2;
Ala1-Thr133). It is produced in an E. coli expression
system and has a molecular weight of 58 kD. Neomycin is used in the fermentation
process but is undetectable in the final product. Ontak is supplied in single
use vials as a sterile, frozen solution intended for intravenous (IV) administration.
Each 2 mL vial of Ontak contains 300 mcg of recombinant denileukin diftitox
in a sterile solution of citric acid (20 mM), EDTA (0.05 mM) and polysorbate
20 ( < 1%) in Water for Injection, USP. The solution has a pH range of 6.9
to 7.2.Last reviewed on RxList: 12/4/2008





Other reviews about Denileukin Diftitox on wordpress

Clinical Development
  by Libby's H*O*P*E*
The drugs, devices, treatments and assays listed below are the subject of clinical trial testing for use against ovarian cancer or solid tumors.ツ Ovarian cancer patients may be […]


ABSTRACT WATCH : PEDIATRIC PULMONOLOGY
  by clinicalpediatric
Asthma-Like Symptoms are Increased in the Metabolic Syndrome Journal of Asthma, 06/05/09 A MCh Test Pre-post Esophageal Acidification in Detecting GER-related Asthma Journal of Asthma, 06/05/09 Diagnosis of tuberculosis: principles […]


PEDIATRIC PULMONOLOGY : JOURNAL WATCH
  by clinicalpediatric
Asthma-Like Symptoms are Increased in the Metabolic Syndrome Journal of Asthma, 06/05/09 A MCh Test Pre-post Esophageal Acidification in Detecting GER-related Asthma Journal of Asthma, 06/05/09 Diagnosis of tuberculosis: principles […]


Eisai and TSD Japan partner on Denileukin Diftitox in Japan
  by silico
Eisai Co Ltd and TSD Japan have announced that they had concluded a license and joint development agreement for the development of denileukin diftitox in Japan. Under the […]


Eisai and Quintiles partner to develop Eisai's anticancer compounds
  by silico
Eisai has announced that it has concluded a strategic collaboration agreement with Quintiles to develop six anticancer compounds in its oncology pipeline to further expedite its Product Creation […]



Other reviews about Denileukin Diftitox on web:

Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors and ... Denileukin diftitox - Wikipedia, the free encyclopedia


Denileukin Diftitox Brand names: Ontakテδづつョ Espaテδεつアol: Denileucina Diftitox (E. coli) Soluciテδεつウn para inyecciテδεつウn Denileukin Diftitox (E Denileukin diftitox: Information from Answers.com


Learn about the prescription medication Ontak (Denileukin Diftitox), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ontak (Denileukin Diftitox) Drug Information: Uses, Side Effects ...


The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the ... Definition of denileukin diftitox - National Cancer Institute Drug ...


Pharmacologic Category Synonyms. Chemotherapy Agent, Miscellaneous; Use: Labeled Indications. Treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells ... Denileukin Diftitox: Drug Information Provided by Lexi-Comp: Merck ...


Denileukin diftitox. On October 15, 2008, the U. S. Food and Drug Administration converted the approval of denileukin diftitox (Ontakテδづつョ, Eisai Medical Research) solution for ... Denileukin diftitox


denileukin diftitox Intravenous patient information. Detailed drug information for the consumer, includes dosage, denileukin diftitox Intravenous side effects and more. denileukin diftitox Intravenous consumer information from Drugs.com


Denileukin diftitox is a targeted therapy. This medication is classified as an biologic response modifier agent. Ontak Denileukin Diftitox, Ontak - Chemotherapy Drugs, Chemo Drug Side ...


Ontakテδづつョ (denileukin diftitox) treats patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) ONTAK | Treatment for cutaneous T-cell lymphoma (CTCL ...


ONTAK テδづつョ (denileukin diftitox) Rx Only WARNING: Only physicians experienced in the use of antineoplastic therapy and management of patients with cancer should use ONTAK (denileukin ... ONTAKテδづつョ (denileukin diftitox)





Featured Reviews

Reviews Levonorgestrel-Releasing Intrauterine System

Mirena Drug Description Mirena (levonorgestrel-releasing) Intrauterine System DRUG DESCRIPTION What are the possible side effects of levonorgestrel intrauterine system (Mirena)? Get emergency medical help if you have severe pain...
Read More  |  Review This
Reviews Influenza Virus Vaccine

Fluarix Drug Description FLUARIX® Influenza Virus Vaccine 2007-2008 Formula DRUG DESCRIPTION What are the possible side effects of influenza virus injectable vaccine? Influenza virus injectable (killed virus) vaccine will...
Read More  |  Review This
Reviews Dasatinib

Sprycel Drug Description SPRYCEL® (dasatinib) Tablet for Oral use DRUG DESCRIPTION What are the possible side effects of dasatinib (Sprycel)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Eovist

Eovist Drug Description EOVIST (gadoxetate disodium) Injection for Intravenous use WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with: ...
Read More  |  Review This
Reviews Bextra

Bextra Drug Description Bextra (valdecoxib) Tablets DRUG DESCRIPTION What are the possible side effects of valdecoxib (Bextra)? Serious skin reactions have occurred in patients taking valdecoxib. These reactions tend to occur within...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....